Literature DB >> 33925808

Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study.

Shaden Melhem1,2, Sarah Steven1,3, Roy Taylor1, Ahmad Al-Mrabeh1.   

Abstract

Cardiovascular disease (CVD) remains a major problem for people with type 2 diabetes (T2DM), and the leading cause of death worldwide. We aimed to determine cardiovascular benefits of weight loss with or without remission of diabetes, and to assess utility of plasma biomarkers. 29 people with T2DM were studied at baseline and after dietary weight loss. Change in plasma adipokines and lipid related markers was examined in relation to weight loss, diabetes remission, 10-year cardiovascular risk (QRISK), and duration of diabetes. QRISK decreased markedly after weight loss (18.9 ± 2.2 to 11.2 ± 1.6%, p < 0.0001) in both responders and non-responders, but non-responders remained at higher risk (15.0 ± 2.0 vs. 5.8 ± 1.6%, p < 0.0001). At baseline, plasma GDF-15 was higher in longer diabetes duration (1.19 ± 0.14 vs. 0.82 ± 0.09 ng/mL, p = 0.034), as was the QRISK (22.8 ± 2.6 vs. 15.3 ± 3.4%, p = 0.031). Leptin, GDF-15 and FGF-21 decreased whereases adiponectin increased after weight loss in responders and non-responders. However, the level of FGF-21 remained higher in non-responders (0.58 [0.28-0.71] vs. 0.25 [0.15-0.42] ng/mL, p = 0.007). QRISK change correlated with change in plasma VLDL1-TG (r = 0.489, p = 0.007). There was a positive correlation between rise in HDL cholesterol and the decrease in leptin (r = 0.57, p = 0.001), or rise in adiponectin (r = 0.58, p = 0.001) levels. In conclusion, weight loss markedly decreases cardiometabolic risk particularly when remission of diabetes is achieved. Leptin, adiponectin, GDF-15 and FGF-21 changes were related to weight loss not remission of diabetes. Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.

Entities:  

Keywords:  Type 2 diabetes; biomarkers; cardiovascular disease; remission; weight loss

Year:  2021        PMID: 33925808     DOI: 10.3390/nu13051465

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  44 in total

1.  Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.

Authors:  Michael E J Lean; Wilma S Leslie; Alison C Barnes; Naomi Brosnahan; George Thom; Louise McCombie; Carl Peters; Sviatlana Zhyzhneuskaya; Ahmad Al-Mrabeh; Kieren G Hollingsworth; Angela M Rodrigues; Lucia Rehackova; Ashley J Adamson; Falko F Sniehotta; John C Mathers; Hazel M Ross; Yvonne McIlvenna; Paul Welsh; Sharon Kean; Ian Ford; Alex McConnachie; Claudia-Martina Messow; Naveed Sattar; Roy Taylor
Journal:  Lancet Diabetes Endocrinol       Date:  2019-03-06       Impact factor: 32.069

2.  The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.

Authors:  Shiu Lun Au Yeung; Shan Luo; C Mary Schooling
Journal:  Diabetologia       Date:  2019-06-03       Impact factor: 10.122

3.  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

Authors:  Sotirios Tsimikas; Ewa Karwatowska-Prokopczuk; Ioanna Gouni-Berthold; Jean-Claude Tardif; Seth J Baum; Elizabeth Steinhagen-Thiessen; Michael D Shapiro; Erik S Stroes; Patrick M Moriarty; Børge G Nordestgaard; Shuting Xia; Jonathan Guerriero; Nicholas J Viney; Louis O'Dea; Joseph L Witztum
Journal:  N Engl J Med       Date:  2020-01-01       Impact factor: 91.245

4.  Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss.

Authors:  Ahmad Al-Mrabeh; Sviatlana V Zhyzhneuskaya; Carl Peters; Alison C Barnes; Shaden Melhem; Aaron Jesuthasan; Benjamin Aribisala; Kieren G Hollingsworth; Georg Lietz; John C Mathers; Naveed Sattar; Michael E J Lean; Roy Taylor
Journal:  Cell Metab       Date:  2019-12-19       Impact factor: 27.287

5.  Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes.

Authors:  Camilla Vavruch; Toste Länne; Mats Fredrikson; Torbjörn Lindström; Carl Johan Östgren; Fredrik H Nystrom
Journal:  Cardiovasc Diabetol       Date:  2015-05-22       Impact factor: 9.951

6.  Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity.

Authors:  Ahmad Al-Mrabeh; Kieren G Hollingsworth; Sarah Steven; Roy Taylor
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

7.  Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies.

Authors:  Reecha Sofat; Jackie A Cooper; Meena Kumari; Juan P Casas; Jacqueline P Mitchell; Jayshree Acharya; Simon Thom; Alun D Hughes; Steve E Humphries; Aroon D Hingorani
Journal:  PLoS Med       Date:  2016-10-18       Impact factor: 11.069

8.  GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans.

Authors:  Satish Patel; Anna Alvarez-Guaita; Audrey Melvin; Debra Rimmington; Alessia Dattilo; Emily L Miedzybrodzka; Irene Cimino; Anne-Catherine Maurin; Geoffrey P Roberts; Claire L Meek; Samuel Virtue; Lauren M Sparks; Stephanie A Parsons; Leanne M Redman; George A Bray; Alice P Liou; Rachel M Woods; Sion A Parry; Per B Jeppesen; Anders J Kolnes; Heather P Harding; David Ron; Antonio Vidal-Puig; Frank Reimann; Fiona M Gribble; Carl J Hulston; I Sadaf Farooqi; Pierre Fafournoux; Steven R Smith; Jorgen Jensen; Danna Breen; Zhidan Wu; Bei B Zhang; Anthony P Coll; David B Savage; Stephen O'Rahilly
Journal:  Cell Metab       Date:  2019-01-10       Impact factor: 27.287

Review 9.  β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies.

Authors:  Ahmad Al-Mrabeh
Journal:  Biomedicines       Date:  2021-02-23

10.  Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population.

Authors:  Paul Welsh; Heather M Murray; Brendan M Buckley; Anton J M de Craen; Ian Ford; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; James Shepherd; Naveed Sattar
Journal:  Diabetes Care       Date:  2008-11-10       Impact factor: 19.112

View more
  4 in total

Review 1.  GDF15: a potential therapeutic target for type 1 diabetes.

Authors:  Soumyadeep Sarkar; John T Melchior; Hayden R Henry; Farooq Syed; Raghavendra G Mirmira; Ernesto S Nakayasu; Thomas O Metz
Journal:  Expert Opin Ther Targets       Date:  2022-02-09       Impact factor: 6.902

2.  Sex differences in intraorgan fat levels and hepatic lipid metabolism: implications for cardiovascular health and remission of type 2 diabetes after dietary weight loss.

Authors:  Aaron Jesuthasan; Sviatlana Zhyzhneuskaya; Carl Peters; Alison C Barnes; Kieren G Hollingsworth; Naveed Sattar; Michael E J Lean; Roy Taylor; Ahmad H Al-Mrabeh
Journal:  Diabetologia       Date:  2021-10-16       Impact factor: 10.122

3.  Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Mengshu Cao; Lina Gu; Lili Guo; Mengying Liu; Tianzhen Wang; Ji Zhang; Huizhe Zhang; Yufeng Zhang; Yanchen Shi; Yichao Zhao; Xiaohua Qiu; Xianhua Gui; Miao Ma; Yaqiong Tian; Xiaoqin Liu; Fanqing Meng; Yonglong Xiao; Lingyun Sun
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

4.  Close association between lifestyle and circulating FGF21 levels: A systematic review and meta-analysis.

Authors:  Zonghao Qian; Yucong Zhang; Ni Yang; Hao Nie; Zhen Yang; Pengcheng Luo; Xiuxian Wei; Yuqi Guan; Yi Huang; Jinhua Yan; Lei Ruan; Cuntai Zhang; Le Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.